The Parliamentary Under-Secretary of State for Health and Social Care (Maggie Throup)
The covid-19 vaccination programme continues to protect the nation against the virus. As of 19 February 2022 over 139 million doses have been provided, including 52.5 million first doses, 48.8 million second doses and 37.9 million third primary and booster doses in the UK. This represents uptake of 91.4% for the first dose, 85% for the second dose and 66.1% for the third primary and booster doses thus far.
Vaccines remain the best protection against the virus and have enabled the gradual and safe removal of restrictions over the past year. As the Government published their “living with covid-19” strategy earlier this week, vaccines continue to be at the heart of the Government’s approach to living with the virus in the future. Therefore, we urge everyone to play their part by taking up the covid-19 vaccine and booster offer without delay.
The independent Joint Committee on Vaccination and Immunisation (JCVI) has published further advice on the covid-19 vaccination programme. Her Majesty’s Government (HMG) has accepted this advice and I am informed that all four parts of the UK intend to follow the JCVI’s advice.
Universal Offer to Children aged 5 to 11:
Children without underlying health conditions are at low risk of serious illnesses from covid-19 and the priority remains for the NHS to offer vaccines to adults and vulnerable young people, as well as to catch-up with other childhood immunisation programmes.
At this time, the JCVI has advised a non-urgent offer of two 10 micrograms doses of the Pfizer covid-19 vaccine to children aged five to 11 years of age who are not in a clinical risk group. The two doses should be offered with an interval of at least 12 weeks between doses. This offer will continue to ensure good protection against potential future waves of covid-19 as we learn to live with this virus.
The NHS is working through updated guidance and will set out how this is going to be operationalised, with deployment expected to begin in due course.
As we learn to live with covid-19 in the UK, the JCVI will review whether, in the longer term, an offer of vaccination to this, and other paediatric age groups, continues to be advised.
As we have done throughout the covid-19 vaccination programme, we will continue to provide information and encouragement to the parents and carers of eligible children to ensure that they make the best decision for their children, whatever it may be. Every parent will have the opportunity to make an informed choice based on their own personal circumstances.
Spring and autumn vaccination programmes:
We know that winter is a time when the threat from covid-19 could be greatest both for individuals and for the NHS. The JCVI has given interim advice that there should be an autumn 2022 programme of vaccinations for those who are at higher risk of severe covid-19; such as the elderly and in clinical risk groups. The JCVI will be offering definitive advice on any recommended autumn programme nearer the time.
However, many of the oldest, and therefore most vulnerable, will have received their most recent vaccine dose in September and October 2021. These individuals are at higher risk of severe covid-19 due to waning of vaccine-induced immunity prior to an autumn programme.
As a precautionary strategy, and to maintain protection in the most vulnerable, the JCVI advises that a spring dose, around six months after the last vaccine dose, should be offered to:
adults aged 75 years and over, and residents living in care homes for older adults; and
individuals aged 12 years and over who are immunosuppressed, as defined in in the UK
Health Safety Agency’s (UKHSA) Green Book.
Eligible individuals aged 18 years and over may be offered a booster vaccination with 30mcg Pfizer/BioNTech (Comirnaty) vaccine or 50mcg Moderna (Spikevax) vaccine. Eligible individuals aged 12 to less than 18 years may be offered a booster vaccination with 30 mcg Pfizer/BioNTech (Comirnaty) vaccine.
With the vaccine offer to all those aged five to 11 years and the spring dose offer to the most vulnerable, I am now updating the House on the liabilities HMG has taken on in relation to further vaccine supply via this statement and the Departmental Minutes laid in Parliament containing a description of the liability undertaken. The agreement to provide indemnity with deployment of further doses increases the statutory contingent liability of the covid-19 vaccination programme.
Deployment of effective vaccines to eligible groups has been and remains a key part of the Government’s strategy to manage covid-19. Willingness to accept the need for appropriate indemnities to be given to vaccine suppliers has helped to secure access to vaccines, with the expected benefits to public health and the economy alike, much sooner than may have been the case otherwise.
Given the exceptional circumstances we are in, and the terms on which developers have been willing to supply a covid-19 vaccine, we along with other nations have taken a broad approach to indemnification proportionate to the situation we are in.
Even though the covid-19 vaccines have been developed at pace, at no point and at no stage of development has safety been bypassed. The MHRA has approved the use of the Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) covid-19 vaccines. These vaccines have satisfied, in full, all the necessary requirements for safety, effectiveness, and quality.
We are providing indemnities in the very unexpected event of any adverse reactions that could not have been foreseen through the robust checks and procedures that have been put in place.
I will update the House in a similar manner as and when other covid-19 vaccines or additional doses of vaccines already in use in the UK are deployed.
HM Treasury has approved the proposal in principle.
[HCWS628]